Evidence map›Paper›PMID 40579768›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2025

Experiences of key populations in multidrug-resistant TB and HIV.

H Nyilana, K Reis, B Seepamore, R Perumal, A Wolf, K Guzman, K R Amico, M Zulu, S Hlathi, X Lu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

H NyilanaCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
K ReisDepartment of Medicine, University of Washington, Seattle, WA, USA.
B SeepamoreCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa;, School of Applied Human Sciences, University of KwaZulu-Natal, Durban, South Africa.
R PerumalCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa;, Division of Pulmonology and Critical Care, Department of Medicine, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
A WolfDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY, USA.
K GuzmanDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY, USA.
K R AmicoUniversity of Michigan School of Public Health, Ann Arbor, MI, USA.
M ZuluCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
S HlathiCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
X LuDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY, USA.
T MabuyiBellhaven Harm Reduction Centre, Durban, South Africa.
N NhlangulelaDenis Hey Centre, Durban, South Africa.
R PerrierDenis Hey Centre, Durban, South Africa.
M WilsonBellhaven Harm Reduction Centre, Durban, South Africa;, Department of Health Behavior, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
G FriedlandDivision of Infectious Diseases, Yale University School of Medicine, New Haven, CT.
K NaidooCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
A DaftaryCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa;, School of Global Health and Dahdaleh Institute of Global Health Research, York University, Toronto, Canada.
J ZelnickGraduate School of Social Work, Touro University, New York City, NY, USA.
M O'DonnellCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa;, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY, USA;, Department of Epidemiology, Columbia University Irving Medical Center, New York City, NY, USA.

Funding

Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaR01AI167795 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2022 to 2026
$2.9M
NIAID NIH HHS R01 AI167795
6 · The paper itself

Abstract

Key populations for multidrug-resistant TB (MDR-TB) face heightened vulnerability due to social, behavioral, and structural barriers, such as poverty, substance use and stigma. Here we illustrate the difficulties faced with a composite personal narrative based on the experiences of two participants in a clinical trial of adherence support interventions for people with MDR-TB and HIV. Addressing these factors through tailored interventions is crucial to improving care engagement and challenging one-size-fits-all approaches to TB prevention.

Indexed as

HIV InfectionsTuberculosis, Multidrug-ResistantAdultAntitubercular AgentsFemaleHumansMaleMedication AdherencePovertySocial StigmaAntitubercular Agents

Identifiers

PMID40579768
PMCPMC13006851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.